Publications by authors named "Mark Kirschbaum"

Claim this Profile
P
Paediatric strategy forum for medicinal product development of cyclin-dependent kinase inhibitors in children and adolescents ACCELERATE in collaboration with the European Medicines Agency With participation of the Food and Drug Administration.
Andrew Dj Pearson, Susan Chi, Theodore W Laetscht, Lynley Marshall, Elizabeth Raetz, Mark Kirschbaum

Eur J Cancer· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Understanding rural pharmacists' perspectives: lived experiences and insights associated with rural recruitment and retention.
Daniel R Terry, Blake Peck, Hoang Phan, Danny Hills, Jaclyn Bishop, Mark Kirschbaum

Rural Remote Health· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sustaining rural pharmacy workforce understanding key attributes for enhanced retention and recruitment.
Daniel Terry, Blake Peck, Danny Hills, Jaclyn Bishop, Mark Kirschbaum

Aust J Rural Health· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Pharmacy Community Apgar Questionnaire: a modified Delphi technique to develop a rural pharmacist recruitment and retention tool.
Daniel R Terry, Blake Peck, Danny Hills, Jaclyn Bishop, Mark Kirschbaum

Rural Remote Health· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Factors contributing to the recruitment and retention of rural pharmacist workforce: a systematic review.
Daniel Terry, Hoang Phan, Blake Peck, Danny Hills, Mark Kirschbaum

BMC Health Serv Res· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factors contributing to the recruitment and retention of rural pharmacist workforce: a systematic review.
Daniel Terry, Hoang Phan, Blake Peck, Danny Hills, Mark Kirschbaum

BMC Health Serv Res· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma.
Joseph M Tuscano, Emanual Maverakis, Susan Groshen, Denice Tsao-Wei, Guillaume Luxardi, Mark Kirschbaum

Clin Cancer Res· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
'
'The public rely on me a lot': Rural pharmacists' perspectives on their roles in oral health care.
Ha Hoang, Tony Barnett, Mark Kirschbaum, Stephanie Dunbar, Rita Wong

Aust J Rural Health· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exercise for reducing falls in people living with and beyond cancer.
Andrew D Williams, Marie-Louise Bird, Sibella Gk Hardcastle, Mark Kirschbaum, Kathryn J Ogden

Cochrane Database Syst Rev· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adverse drug reactions in primary care: a scoping review protocol.
Hanan Khalil, Mark Kirschbaum

JBI Database System Rev Implement Rep· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II study of vascular endothelial growth factor trap (Aflibercept, NSC 724770) in patients with myelodysplastic syndrome: a California Cancer Consortium Study.
Mark H Kirschbaum, Paul Frankel, Timothy W Synold, Jasmine Zain, David Claxton

Br J Haematol· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I pharmacodynamic study of GTI-2040, an antisense oligonucleotide against ribonuclotide reductase, in acute leukemias: a California Cancer Consortium study.
Mark H Kirschbaum, Paul Frankel, Timothy W Synold, Zhiliang Xie, Yun Yen

Leuk Lymphoma· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mental health first aid training needs of Australian community pharmacists.
Mark Kirschbaum, Gregory Peterson, Heather Bridgman

Curr Pharm Teach Learn· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia.
Michael Andreeff, Kevin R Kelly, Karen Yee, Sarit Assouline, Roger Strair, Mark Kirschbaum

Clin Cancer Res· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative data.
Susan E Bates, Robin Eisch, Alexander Ling, Douglas Rosing, Maria Turner, Mark H Kirschbaum

Br J Haematol· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma.
Robert Chen, Paul Frankel, Leslie Popplewell, Tanya Siddiqi, Nora Ruel, Mark Kirschbaum

Haematologica· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study.
Mark H Kirschbaum, Kenneth A Foon, Paul Frankel, Christopher Ruel, Bernadette Pulone

Leuk Lymphoma· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome.
Mark Kirschbaum, Ivana Gojo, Stuart L Goldberg, Christopher Bredeson, Lisa A Kujawski

Br J Haematol· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432.
Harry P Erba, Megan Othus, Roland B Walter, Mark H Kirschbaum, Martin S Tallman

Leuk Res· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial.
Nitin Jain, Emily Curran, Neil M Iyengar, Ernesto Diaz-Flores, Rangesh Kunnavakkam, Mark H Kirschbaum

Clin Cancer Res· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study.
Anas Younes, Anna Sureda, Dina Ben-Yehuda, Pier Luigi Zinzani, Tee-Chuan Ong, Mark Kirschbaum

J Clin Oncol· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I study in adults of clofarabine combined with high-dose melphalan as reduced-intensity conditioning for allogeneic transplantation.
Mark H Kirschbaum, Anthony S Stein, Leslie Popplewell, Maria Delioukina, Robert Chen

Biol Blood Marrow Transplant· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517.
Mark H Kirschbaum, Bryan H Goldman, Jasmine M Zain, James R Cook, Lisa M Rimsza

Leuk Lymphoma· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Histone deacetylase inhibitors and Hodgkin's lymphoma.
Mark H Kirschbaum

Lancet Oncol· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and microRNA levels.
Leo Kretzner, Anna Scuto, Pamela M Dino, Claudia M Kowolik, Jun Wu, Mark H Kirschbaum

Cancer Res· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis